804,262 Shares in Organon & Co. (NYSE:OGN) Bought by Philip James Wealth Mangement LLC

Philip James Wealth Mangement LLC bought a new stake in Organon & Co. (NYSE:OGN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 804,262 shares of the company’s stock, valued at approximately $15,386,000. Organon & Co. comprises approximately 1.9% of Philip James Wealth Mangement LLC’s investment portfolio, making the stock its 8th biggest position. Philip James Wealth Mangement LLC owned 0.31% of Organon & Co. as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. LSV Asset Management lifted its holdings in shares of Organon & Co. by 47.3% during the second quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock worth $136,843,000 after purchasing an additional 2,121,940 shares during the period. Wedge Capital Management L L P NC bought a new stake in shares of Organon & Co. in the 2nd quarter valued at about $33,573,000. Kahn Brothers Group Inc. increased its stake in shares of Organon & Co. by 3,242.4% in the first quarter. Kahn Brothers Group Inc. now owns 1,180,204 shares of the company’s stock valued at $22,188,000 after buying an additional 1,144,894 shares during the period. Boston Partners bought a new position in shares of Organon & Co. during the first quarter worth about $19,306,000. Finally, AQR Capital Management LLC raised its position in shares of Organon & Co. by 39.8% during the second quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after acquiring an additional 988,336 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on OGN. JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and upped their target price for the company from $18.00 to $20.00 in a report on Friday, September 6th. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Trading Down 0.6 %

Shares of Organon & Co. stock traded down $0.09 on Friday, hitting $16.03. 186,636 shares of the company’s stock traded hands, compared to its average volume of 2,230,179. The company has a fifty day moving average of $18.89 and a two-hundred day moving average of $20.06. Organon & Co. has a one year low of $10.84 and a one year high of $23.10. The company has a market capitalization of $4.13 billion, a price-to-earnings ratio of 3.20, a price-to-earnings-growth ratio of 0.76 and a beta of 0.84. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.17.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Organon & Co.’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.78 earnings per share. As a group, sell-side analysts expect that Organon & Co. will post 4.04 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be paid a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 6.99%. The ex-dividend date is Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is currently 22.22%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.